These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26304767)

  • 1. Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs.
    Morton TL; Devarakonda K; Kostenbader K; Montgomery J; Barrett T; Webster L
    Pain Med; 2016 Mar; 17(3):539-550. PubMed ID: 26304767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.
    Morton T; Kostenbader K; Montgomery J; Devarakonda K; Barrett T; Webster L
    Postgrad Med; 2014 Jul; 126(4):20-32. PubMed ID: 25141240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
    Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
    Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
    Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
    J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Human Abuse Potential of Oxycodone DETERx
    Kopecky EA; Fleming AB; Levy-Cooperman N; O'Connor M; M Sellers E
    J Clin Pharmacol; 2017 Apr; 57(4):500-512. PubMed ID: 27669664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
    Backonja M; Webster LR; Setnik B; Bass A; Sommerville KW; Matschke K; Malhotra BK; Wolfram G
    Am J Drug Alcohol Abuse; 2016 Sep; 42(5):539-549. PubMed ID: 27211522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
    Setnik B; Bramson C; Bass A; Levy-Cooperman N; Malhotra B; Matschke K; Sommerville KW; Wolfram G; Geoffroy P
    J Clin Pharmacol; 2015 Dec; 55(12):1351-61. PubMed ID: 26011742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
    Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
    Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
    Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
    J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
    Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
    Setnik B; Roland CL; Cleveland JM; Webster L
    Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
    Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
    Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
    Setnik B; Sommerville K; Goli V; Han L; Webster L
    Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.
    Webster LR; Kopecky EA; Smith MD; Fleming AB
    Pain Med; 2016 Jun; 17(6):1112-30. PubMed ID: 26814256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
    Smith MD; Webster LR; Lawler J; Lindhardt K; Dayno JM
    Pain Med; 2017 May; 18(5):898-907. PubMed ID: 27633773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.